Bipolar disorder

JNJ

Pharma

J&J touts Caplyta win in 1 of 2 bipolar manic episode studies

Caplyta helped deliver rapid improvement in manic symptoms and overall illness severity versus placebo in adults with bipolar-related manic episodes.

Fraiser Kansteiner Sep 21, 2026 2:30pm

Teva

Fierce Biotech

Teva saddles up as bidder for bankrupt BioXcel’s CNS assets

Aug 28, 2026 9:17am

JNJ

J&J acquires CNS specialist Intra-Cellular for $14.6B

Jan 13, 2025 10:29am

depression major depressive disorder

Intra-Cellular closing in on major depression nod for Caplyta

Jun 18, 2024 11:40am

FDA

15 years later, Vanda secures another FDA nod for Fanapt

Apr 3, 2024 11:04am

Alkermes

Alkermes reports strong trajectory for Lybalvi, shares up 10%

Feb 15, 2024 1:10pm